Novel Therapies for Eosinophilic Disorders.
Novel Therapies for Eosinophilic Disorders.
复制标题
DOI：
10.1016/j.iac.2015.05.007
复制
发表时间：
2015-08
影响因子：
2.6
通讯作者：
Bochner BS
中科院分区：
文献类型：
--
作者：
Bochner BS
目前治疗嗜酸性粒细胞性疾病的方法是有限的。大多数治疗方法仍然是经验性的，没有来自对照临床试验的数据支持，涉及开发用于治疗其他疾病的药物的标签外使用，并且倾向于严重依赖糖皮质激素和其他具有显著毒性的药物的使用。还缺乏经过验证的结果指标和临床相关的生物标志物，以帮助指导治疗选择，疗效和疾病活动的评估。在过去的十年中，在发现、临床前开发和临床试验各种生物制剂和小分子方面取得了很大进展，这些生物制剂和小分子有可能直接或间接影响嗜酸性粒细胞、嗜酸性粒细胞炎症和嗜酸性粒细胞活化的后果。特别先进的是针对嗜酸性粒细胞选择性细胞因子及其受体的生物制剂的研究。此外，近年来已获得FDA批准用于非嗜酸性粒细胞相关适应症的其他疗法可考虑用于嗜酸性粒细胞疾病的测试。总的来说，对于那些患有嗜酸性粒细胞疾病的人来说，治疗选择的前景从未如此光明，许多新的选择即将出现。
Current therapies for eosinophilic disorders are limited. Most treatment approaches remain empirical, are not supported by data from controlled clinical trials, involve the off-label use of agents developed for treatment of other diseases, and tend to rely heavily on the use of glucocorticoids and other agents with significant toxicity. Also lacking are validated outcome metrics and clinically relevant biomarkers to help guide treatment choices, efficacy and assessment of disease activity. Over the last decade, great progress has been made in the discovery, preclinical development and clinical testing of a variety of biologics and small molecules that have the potential to directly or indirectly influence eosinophils, eosinophilic inflammation and the consequences of eosinophil activation. Particularly advanced are studies with biologics that target eosinophil-selective cytokines and their receptors. In addition, other therapies that have received FDA approval in recent years for non-eosinophil-related indications can be considered for testing in eosinophilic disorders. Overall, the landscape of therapeutic options for those suffering from eosinophilic disorders has never been brighter, with many new choices on the horizon.